Given the current uncertainty regarding the proper identification ofpathological diagnosis in patients with CBS and other phenotypes associated withCBD, trying AChEIs may be reasonable since patients with certain underlyingpathologies, such as AD, may experience some improvement. This evidence concerns the gene CBS and Alzheimer disease.